Background: The optimal surveillance strategy for low-risk branch-duct intraductal papillary mucinous neoplasms (BD-IPMN) remains unclear. We aim to evaluate the natural history of low-risk BD-IPMN/indeterminate pancreatic cysts to determine optimal surveillance intervals.
Methods: We conducted a retrospective cohort study of patients with radiologically-diagnosed low-risk BD-IPMN/indeterminate pancreatic cysts from 1998 to 2021 at a tertiary referral center. Low-risk BD-IPMN, worrisome features (WF) and high-risk stigmata (HRS) were defined as per existing guidelines. Patients were grouped into three categories based on cyst size at diagnosis: <10 mm, 10-19 mm and 20-29 mm. The size distribution and cumulative incidence of WF and HRS development were charted annually for the first five years.
Results: We studied 1668 patients, with 794 (47.6 %), 652 (39.1 %) and 222 (13.3 %) with cysts <10 mm, 10-19 mm and 20-29 mm at baseline respectively. Overall WF and HRS development was seen in 11.7 % and 1.4 % of patients respectively, with higher proportion of WF (6.8 vs 9.8 vs 34.7 %, p < 0.001) and HRS (0.9 vs 1.4 vs 3.6 %, p = 0.011) development with increasing baseline size category. Cysts <10 mm had 94.3 % < 30 mm at five years, 2.0 % WF at one year and a single case of HRS at two years. Cysts 10-19 mm had 94.7 % < 30 mm at five years, 2.2 % WF at one year and the first incident case of HRS at one year. Cysts 20-29 mm had 63.8 % < 30 mm at five years, 9.5 % WF and 1.1 % (4 cases) HRS by one year.
Conclusion: Baseline cyst size can be used to guide surveillance intervals for low-risk BD-IPMN/indeterminate pancreatic cysts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pan.2024.11.014 | DOI Listing |
Gastrointest Endosc
January 2025
Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Background & Aims: Pancreatic cysts often pose challenges in predicting malignant progression. Next-generation sequencing has become an appealing ancillary diagnostic test. The diagnostic performance is well characterized, but the impact on clinical management remains unclear.
View Article and Find Full Text PDFJ Cyst Fibros
January 2025
Leeds Institute of Medical Research, University of Leeds, School of Medicine, Leeds, United Kingdom; The Leeds Adult CF Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. Electronic address:
Background: Whether improvements in gastrointestinal (GI) symptoms observed with Elexacaftor/Tezacaftor/Ivacaftor (ETI) treatment are sustained in the longer-term requires exploration. This study investigated how GI-symptoms change with longer-term ETI use in pancreatic insufficient adults with cystic fibrosis (awCF).
Methods: Participants completed up to three abdominal symptom questionnaires, employing the validated CFAbd-Score.
Intern Med
January 2025
Department of Nephrology, The University of Osaka Graduate School of Medicine, Japan.
We encountered a family with hereditary renal failure, renal medullary cysts, pancreatic hypoplasia, hypomagnesemia, liver enzyme abnormalities, and diabetes mellitus (DM). We identified a novel heterozygous variant of HNF1B (NM_000458.4:c.
View Article and Find Full Text PDFHealth Sci Rep
January 2025
Gerhard-Domagk Institute of Pathology University Hospital Muenster (UKM) Muenster Germany.
Background And Aims: Benign lesions, inflammation, cysts and pseudocysts, as well as neoplasms of the exocrine and endocrine parts of the pancreas can be easily identified using cytological methods. The sensitivity and specificity can be increased with the help of additional examination methods. The sensitivity of intraoperative rapid cytology reaches about 99%.
View Article and Find Full Text PDFEndosc Ultrasound
December 2024
Department of Gastroenterology, the First Medical Center, Chinese PLA General Hospital, Beijing 100083, China.
Background And Objectives: An accurate diagnosis is crucial for the clinical management of pancreatic cystic neoplasm (PCN). EUS-guided through-the-needle biopsy (EUS-TTNB) is a novel technique for improving the accuracy of PCN diagnosis. There is insufficient evidence about the efficacy of EUS-TTNB.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!